Adjuvant Holdings Co.,Ltd.
Adjuvant Holdings Co.,Ltd. (4929.T) Financial Performance & Income Statement Overview
Explore the financials of Adjuvant Holdings Co.,Ltd. (4929.T), including yearly and quarterly data on income, cash flow, and balance sheets.
Adjuvant Holdings Co.,Ltd. (4929.T) Income Statement & Financial Overview
Analyze Adjuvant Holdings Co.,Ltd.’s 4929.T earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $847.28M | $1.17B | $1.02B | $1.06B |
| Cost of Revenue | $324.03M | $383.00M | $373.64M | $360.83M |
| Gross Profit | $523.25M | $788.00M | $643.24M | $702.07M |
| Gross Profit Ratio | $0.62 | $0.67 | $0.63 | $0.66 |
| R&D Expenses | $0.00 | $0.00 | $34.00M | $38.00M |
| SG&A Expenses | $594.78M | $645.00M | $555.85M | $662.12M |
| Operating Expenses | $594.78M | $645.00M | $589.85M | $700.12M |
| Total Costs & Expenses | $918.81M | $1.03B | $963.49M | $1.06B |
| Interest Income | $1.59M | $0.00 | $164000.00 | $21000.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $28.75M | $31.25M | $0.00 | $37.90M |
| EBITDA | -$45.92M | $174.25M | $53.39M | $62.27M |
| EBITDA Ratio | -$0.05 | $0.15 | $0.05 | $0.06 |
| Operating Income | -$71.53M | $143.00M | $53.39M | $1.94M |
| Operating Income Ratio | -$0.08 | $0.12 | $0.05 | $0.002 |
| Other Income/Expenses (Net) | -$3.14M | $8.00M | -$10.03M | $22.43M |
| Income Before Tax | -$74.66M | $151.00M | $43.36M | $24.38M |
| Income Before Tax Ratio | -$0.09 | $0.13 | $0.04 | $0.02 |
| Income Tax Expense | -$9.12M | $63.00M | $38.68M | $10.84M |
| Net Income | -$65.54M | $88.00M | $4.68M | $13.54M |
| Net Income Ratio | -$0.08 | $0.08 | $0.005 | $0.01 |
| EPS | -$8.18 | $10.98 | $0.58 | $1.69 |
| Diluted EPS | -$8.18 | $10.98 | $0.58 | $1.69 |
| Weighted Avg Shares Outstanding | $8.008M | $8.02M | $8.01M | $8.001M |
| Weighted Avg Shares Outstanding (Diluted) | $8.008M | $8.02M | $8.01M | $8.001M |
Over the past four quarters, Adjuvant Holdings Co.,Ltd. demonstrated steady revenue growth, increasing from $1.06B in Q1 2024 to $847.28M in Q4 2024. Operating income reached -$71.53M in Q4 2024, maintaining a consistent -8% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$45.92M, reflecting operational efficiency. Net income dropped to -$65.54M, with EPS at -$8.18. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan